Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early

Dow Jones

02/25

By Chris Wack

Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance.

The company said 1,939 patients were enrolled in 43 countries and more than 500 sites.

Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 25, 2026 10:56 ET (15:56 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2614394460"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614394460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614394460?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614394460","market":"sg","top_or_hot":-1,"title":"Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n</p>\n<p>\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n</p>\n<p>\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 10:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex Shares Rise After Barzolvolimab Study Completes Enrollment Early\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-25 23:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n</p>\n<p>\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n</p>\n<p>\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 10:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDX","symbol_name":"塞德斯醫療","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614394460","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614394460","pubTimestamp":1772034960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance.The company said 1,939 patients were enrolled in 43 countries and more than 500 sites.Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDX":"塞德斯医疗","BK4139":"生物科技"},"translate_title":"Barzolvolimab研究提前完成入组后Celldex股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance. \n\n\n  The company said 1,939 patients were enrolled in 43 countries and more than 500 sites. \n\n\n  Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 10:56 ET (15:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}